华夏源

Huaxia Yuan, also known as S-Evans Bioscience, is a prominent Chinese biotechnology company specializing in the development and clinical application of stem cell therapies and regenerative medicine. Founded in 2016 and headquartered in Shanghai, the company operates a comprehensive value chain including a large-scale Life Bank for cell storage, advanced R&D centers, and GMP-certified manufacturing facilities. Their primary therapeutic focus is on mesenchymal stem cells (MSCs) derived from umbilical cord and adipose tissues, targeting a variety of refractory conditions such as graft-versus-host disease, liver cirrhosis, and osteoarthritis. With several programs in Phase 1 and Phase 2 clinical trials, Huaxia Yuan is a key player in China's rapidly evolving cell therapy sector. The company integrates cutting-edge biotechnology with clinical research through partnerships with leading hospitals and academic institutions.